Peptides in Dermatology — What Clinicians Need to Know Now
Key Clinical Summary
Investigational Peptides in Dermatology: HHS Compounding Policy, Safety, and Clinical Evidence
-
Regulatory status: The proposed HHS policy would permit conditional compounding of 6 investigational peptides but does not constitute FDA approval or establish safety and efficacy. Dermatologic applications remain investigational.
-
Emerging applications: KPV (anti-inflammatory potential), BPC-157 (tissue repair), thymosin beta (wound healing), and MOTS-c (metabolic/mitochondrial pathways) have proposed therapeutic mechanisms, but convincing human clinical trial evidence remains limited.
-
Clinical considerations: Evaluate purity, sterility, dosing, immunogenicity, systemic effects, and long-term safety. Counsel patients on the distinction between mechanistic promise and demonstrated clinical benefit, address misinformation, and discuss established treatment alternatives.
Reviewed by Riya Gandhi, MA, Associate Editor of Immunology Group
Dr Dean Berman discusses the proposed HHS policy on compounded peptides, including BPC-157, KPV, and TB-500, and their potential applications in dermatology. Learn why regulatory discretion does not constitute FDA approval, what evidence gaps and safety concerns remain, and how dermatologists can evaluate investigational peptides, address misleading claims, and counsel patients using evidence-based guidance.
Dean Berman, MD, is a longevity and aesthetic medicine physician, assistant professor of Longevity at the Geneva College of Longevity Science, and Global VP Medical at Alma Lasers. He specializes in aesthetic medicine, longevity science, and peptide-based therapies.
Transcript
Dr Berman: Hello everyone. My name is Dr Dean Berman. I'm an assistant professor for longevity in Switzerland. I'm located in Vienna, Austria, and I’ve worked for nearly the last 20 years as an aesthetic physician. I am also the global vice president of Alma Lasers.
What does the proposed HHS policy on peptide compounding change for clinicians, and what important regulatory and safety limitations remain?
Dr Berman: Well, peptides have been around really for, I dare to say, millions of years. And apparently, they just hired a really good PR agency because seriously they're fascinating because they allow us to explore how cells communicate, and medicine is gradually moving from treating the consequences of biological problems toward understanding the signals behind them. And that's a very exciting shift. Although judging by social media, you would think today that peptides already solved everything, including world peace. But peptides are actually very specific. So, we need to know what we are talking about when we are talking about peptides because to say peptides is a little bit like saying cars. Some people will analyze cars based on their manufacturer. Some of them will analyze them based on electric vs fuel, some of them by colors. Same goes with peptides. With peptides, there are so many different options, so many different mechanisms. And I think that for us as health care professionals, it is important to always remember what is the pathophysiology that is standing behind those peptides. Once we understand the pathophysiology, it is much easier for us to understand what is the role of the peptides, what are the different indications that we can address, and how we should address them.
Among the 6 peptides under consideration, which have the most compelling scientific rationale for dermatologic applications and where are the greatest evidence gaps?
Dr Berman: Okay, so I think it's really an important development. The HHS has proposed a more controlled pathway for compounding the 6 investigational peptides on the very specific conditions. But first of all, let’s be very clear, this is not FDA approval. Nobody has suddenly declared that those molecules are safe and effective. It's a regulatory opening, not a scientific correlation. Hopefully, it will encourage better research rather than just better marketing. Now, personally, I am super interested in 3 of those 6 peptides for dermatological reasons: KPV for its anti-inflammatory potential, BPC-157 for the tissue repair, and the broader thymosin beta for wound healing. So, those 3 peptides are super relevant for every derm out there. MOTS-c is also fascinating from a metabolic and mitochondrial perspective, but here's the catch. Fascinating biology doesn't automatically translate into effective treatments. At the moment, we have more interesting mechanisms than convincing human trials. Fortunately, curiosity is free. Clinical trials unfortunately are not. So, we need to understand what we can achieve knowing that information.
What are the most important safety concerns clinicians should consider when evaluating compounded peptides, particularly regarding purity, dosing, and long-term effects?
Dr Berman: So, the assumption that natural means safe is basically wrong. Arsenic is natural, so is copra. Now, I wouldn't recommend either one of them as a wellness supplement, and I really hope our audience is listening well. With investigational peptides, we need to consider purity, sterility, systemic effects, immunogenicity, and long-term safety. And we shouldn't mistake the absence of reported complications for evidence of safety, particularly when hardly anyone has been studied. I'm always laughing when a patient is coming to me and asking me about certain peptides that only have data on rats or mice. So, I'm always asking them, "Is your name Mickey? Do you have a tail? Then why do you assume that what works on mice would work exactly the same on you?" So, we have a role, we are the gatekeepers at the end of the day, and we have a role and responsibility to translate the information that we've got on peptides to our patients as we have with anything else regarding medicine.
So, it's true that peptides today, as I've mentioned before, have an excellent PR agency. They're doing an amazing job, but we need to understand that at the end of the day, those are still powerful medications and as such, they might have some complications, some adverse effect, and it is our responsibility to educate our patients. I really love this because I'm a huge believer in medical education and I look at it as an opportunity. So, I'm trying to make an excellent lemonade out of those lemons, but I don't want anyone to be fooled and to fall into the social media trap. So, for all of the health care professionals out there, I would say educate yourself in order for us to educate our patients.
When patients ask about peptides they have encountered through social media or longevity clinics, how should dermatologists counsel them without overstating potential benefits or dismissing emerging science?
Dr Berman: So, first of all, I don't roll my eyes, at least not visibly. I actually love curious patients. I just want their curiosity to be accompanied by reliable information and that's not always happening. So, we discussed what the peptide is supposed to do and then what the evidence actually shows. We also need to discuss the alternatives. It's equally important. My job, and just like any other doctor out there, is not to kill the enthusiasm. It's to make sure that the enthusiasm survives contact with science. I think that once we do this, I mean, we need to keep an open mind. And if I would have told our audience the stories that happened in my clinic in the last nearly 20 years, they will burst out in tears. But it is an opportunity to educate, it's an opportunity to teach, it's an opportunity also to absorb what arrives to the patients on the other side, because we might think that we know something, but the way that it's been translated and transformed to our patients might be completely different. So, having said that, I think that I welcome those types of patients. I welcome all types of patients, and I take this amazing opportunity as a way to teach them the right things about peptides, just like I do when they come and they ask me about injectables or energy-based devices and so on.
What principles do you believe dermatologists should keep in mind when discussing investigational peptides with patients?
Dr Berman: First of all, don't be afraid of peptides, but also don't fall in love with them either. Understand their biology, question the claim, and follow the evidence. I think peptides have a fascinating future in dermatology, but let's remember, popularity is not a clinical endpoint. Otherwise, we'll all be prescribing TikTok. So, use your mind, ask the right questions before you prescribe it, and once you do prescribe it, enjoy the results because if you decided to prescribe those specific types of peptides, probably they will have a wonderful effect on your patient's skin appearance and results.


